study the effects of allopurinol in patients with non-alcoholic fatty liver disease

study the effects of Allopurinol on liver enzymes and grade of fatty liver on ultrasound in patients with non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180404039187N2

Enrollment

100

Registered

2018-11-23

Start date

2017-01-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: consumption of 100 mg Allopurinol daily for 6 months. Intervention 2: Control group: routin care.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: patients whom have non-alcoholic fatty liver disease based on the ultrasound and laboratory tests patients whom have non-symptomatic hyperuricemia (serum uric acid >7 mg/dl for men and >6.5 mg/dl for women)

Exclusion criteria

Exclusion criteria: pregnancy and lactation allergy to Allopurinol or its contents use of alcohol patients with renal deficiency with creatinine clearance (GFR) <30 mg/ml simultaneous use of drugs which have interaction with Allopurinol (mercaptopurine, azathioprine, ...) patients who have had gout or who are using uricosuric agents or thiazide diuretics

Design outcomes

Primary

Measure	Time frame
Serum liver enzymes AST and ALT and grade of fatty liver based on ultrasound. Timepoint: at the beginning and 3 and 6 months later. Method of measurement: laboratory tests and ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Elnaz Shaseb

Tabriz University of Medical Sciences

elnaz_shaseb_64@yahoo.com+98 41 3334 1449

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026